ELI LILLY & CO

Explore Eli Lilly’s latest EU approval for Jaypirca, Medicare coverage of GLP‑1 obesity drugs, and a GenAI “Memory Radio” campaign—showcasing growth and innovation.

Discover how Eli Lilly’s Q1 2026 earnings outpaced expectations, propelling GLP‑1 sales, market confidence, and a bullish outlook for investors.

Explore Eli Lilly’s Supreme Court patent battle, fresh clinical‑trial wins, and investor outlook—why LLY’s stock may rise amid legal challenges.

Discover how Eli Lilly’s clinical wins in obesity and neurology, plus strategic China‑India expansions, are driving market confidence and future growth.

Discover how Eli Lilly’s new diabetes‑obesity drug, expanded Olumiant approval, and AI‑powered LillyPod partnership are reshaping its competitive edge and investor appeal.

Explore how Eli Lilly’s $2.4 B acquisition of Orna Therapeutics boosts its in‑vivo CAR‑T platform, advancing next‑generation cell therapies and expanding oncology and immunology portfolios.

Explore how Eli Lilly’s AI‑driven obesity partnership with Nimbus Therapeutics, market‑cap momentum, and strategic pricing moves fuel its growth toward a $1 trillion milestone.

Discover how Eli Lilly’s $1 trillion valuation surge is driven by GLP‑1 drugs like Mounjaro and Zepbound, Medicare pricing moves, and strategic R&D pivots for future growth.

Explore how Eli Lilly’s $74 % price cut and eloralintide’s Phase 2 success are reshaping the obesity‑drug market, boosting shares and investor confidence.

Discover how Eli Lilly’s record Q3 earnings and a Medicare price‑cut deal for weight‑loss drugs are propelling the company’s stock and reshaping the U.S. obesity‑drug market.